We still need your help to ensure that Canadians affected by PAH have access to any and all Health Canada-approved treatments.

The PAH community is hopeful that provincial and territorial governments will continue to support PAH patients and fund all remaining Health Canada-approved treatments, such as Opsumit (macitentan), which is currently accessible through public funding only in Québec.

Please stay tuned to our social channels and this website to learn how you can take action for PAH once again.

Opsumit Public Reimbursement Position Paper

Click here to download PHA Canada's position paper (May 2019)

PHA Canada serves as  a resource for all patients and families affected by the various forms of pulmonary hypertension. Through advocacy, we aim to raise public awareness and rally support around the issues affecting the PH community to ensure its voice is heard and needs are met by government decision-makers.

These issues include ensuring all PH patients have publicly funded access to new and existing treatments—at diagnosis and beyond.


PHA Canada helps to empower and provide support to patients, caregivers, family and friends, as well as members of the PH medical community by advocating to the federal, provincial and territorial governments on issues that are important to our community. Your support can make a significant difference in this work. 



Become a PH advocate and lend your voice to our efforts!

Visit to find out how you can get involved.

If you have any questions, would like to get involved, or need more information, please contact us at


Get the latest on PH treatments, community events and more when you subscribe to our newsletter